These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26660184)

  • 21. Drug screening in medical examiner casework by high-resolution mass spectrometry (UPLC-MSE-TOF).
    Rosano TG; Wood M; Ihenetu K; Swift TA
    J Anal Toxicol; 2013 Oct; 37(8):580-93. PubMed ID: 23999055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid orthogonal screening of forensic drugs using a compact UHPLC-PDA/SQD; a complement to GC-MS.
    Li L; Quintero X
    Forensic Sci Int; 2021 Jan; 318():110565. PubMed ID: 33214009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology.
    Marquet P
    Ther Drug Monit; 2002 Apr; 24(2):255-76. PubMed ID: 11897972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suspect Screening Using LC-QqTOF Is a Useful Tool for Detecting Drugs in Biological Samples.
    Colby JM; Thoren KL; Lynch KL
    J Anal Toxicol; 2018 May; 42(4):207-213. PubMed ID: 29309651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mass Spectrometry for Research and Application in Therapeutic Drug Monitoring or Clinical and Forensic Toxicology.
    Maurer HH
    Ther Drug Monit; 2018 Aug; 40(4):389-393. PubMed ID: 29750739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens.
    Guale F; Shahreza S; Walterscheid JP; Chen HH; Arndt C; Kelly AT; Mozayani A
    J Anal Toxicol; 2013; 37(1):17-24. PubMed ID: 23118149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a sensitive untargeted liquid chromatography-high resolution mass spectrometry screening devoted to hair analysis through a shared MS2 spectra database: A step toward early detection of new psychoactive substances.
    Fabresse N; Larabi IA; Stratton T; Mistrik R; Pfau G; Lorin de la Grandmaison G; Etting I; Grassin Delyle S; Alvarez JC
    Drug Test Anal; 2019 May; 11(5):697-708. PubMed ID: 30394697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compound identification in forensic toxicological analysis with untargeted LC-MS-based techniques.
    Oberacher H; Arnhard K
    Bioanalysis; 2015 Nov; 7(21):2825-40. PubMed ID: 26563687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Application of liquid chromatography-high resolution mass spectrometry in toxicological screening].
    Li XW; Shen BH; Zhuo XY
    Fa Yi Xue Za Zhi; 2011 Oct; 27(5):376-81. PubMed ID: 22259869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LC-MS/MS techniques for high-volume screening of drugs of abuse and target drug quantitation in urine/blood matrices.
    Eichhorst JC; Etter ML; Hall PL; Lehotay DC
    Methods Mol Biol; 2012; 902():29-41. PubMed ID: 22767105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitreous humor as an alternative matrix for comprehensive drug screening in postmortem toxicology by liquid chromatography-time-of-flight mass spectrometry.
    Pelander A; Ristimaa J; Ojanperä I
    J Anal Toxicol; 2010; 34(6):312-8. PubMed ID: 20663283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology.
    Maurer HH
    Clin Biochem; 2005 Apr; 38(4):310-8. PubMed ID: 15766732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances of liquid chromatography-(tandem) mass spectrometry in clinical and forensic toxicology.
    Peters FT
    Clin Biochem; 2011 Jan; 44(1):54-65. PubMed ID: 20709050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time-of-flight mass spectrometry (TOF-MS) exact mass database for benzodiazepine screening.
    Hayashida M; Takino M; Terada M; Kurisaki E; Kudo K; Ohno Y
    Leg Med (Tokyo); 2009 Apr; 11 Suppl 1():S423-5. PubMed ID: 19362868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of saliva and fingerprints as alternative specimens to urine and blood in forensic drug testing.
    Kuwayama K; Miyaguchi H; Yamamuro T; Tsujikawa K; Kanamori T; Iwata YT; Inoue H
    Drug Test Anal; 2016 Jul; 8(7):644-51. PubMed ID: 26074137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pitfalls in drug testing by hyphenated low- and high-resolution mass spectrometry.
    Maurer HH
    Drug Test Anal; 2020 Feb; 12(2):172-179. PubMed ID: 31804756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of High-Resolution UPLC-MSE/TOF Confirmation in Forensic Urine Drug Screening by UPLC-MS/MS.
    Rosano TG; Ohouo PY; Wood M
    J Anal Toxicol; 2019 Jun; 43(5):353-363. PubMed ID: 30753546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicological Drug Screening using Paper Spray High-Resolution Tandem Mass Spectrometry (HR-MS/MS).
    McKenna J; Jett R; Shanks K; Manicke NE
    J Anal Toxicol; 2018 Jun; 42(5):300-310. PubMed ID: 29377996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the future of (ultra) high performance liquid chromatography coupled to low and high resolution mass spectrometry for toxicological drug screening?
    Maurer HH
    J Chromatogr A; 2013 May; 1292():19-24. PubMed ID: 22964051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control.
    Maurer HH
    Clin Chem Lab Med; 2004; 42(11):1310-24. PubMed ID: 15576292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.